Evidence map›Paper›PMID 40164870›Full record

ArticleOncogene2025

Active R-RAS2/TC21 prevents cell cycle arrest and morphological alterations in mouse embryonic fibroblasts lacking RAS proteins.

Isabel Fernández-Pisonero, L Francisco Lorenzo-Martín, Mattias Drosten, Eugenio Santos, Mariano Barbacid, Balbino Alarcón, Xosé R Bustelo

Abstract read
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Isabel Fernández-PisoneroMolecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC and Universidad de Salamanca, Salamanca, Spain.ORCID http://orcid.org/0000-0002-5130-2143
L Francisco Lorenzo-MartínMolecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC and Universidad de Salamanca, Salamanca, Spain.ORCID http://orcid.org/0000-0003-4717-9338
Mattias DrostenMolecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC and Universidad de Salamanca, Salamanca, Spain.ORCID http://orcid.org/0000-0002-3205-456X
Eugenio SantosMolecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC and Universidad de Salamanca, Salamanca, Spain.ORCID http://orcid.org/0000-0003-3565-0321
Mariano BarbacidCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
Balbino AlarcónCentro de Biología Molecular Severo Ochoa, CSIC and Universidad Autónoma de Madrid, Madrid, Spain.ORCID http://orcid.org/0000-0001-7820-1070
Xosé R BusteloMolecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC and Universidad de Salamanca, Salamanca, Spain. xbustelo@usal.es.ORCID http://orcid.org/0000-0001-9398-6072

Funding

Consejería de Educación, Junta de Castilla y León (Consejería de Educación de la Junta de Castilla y León) CLU-2023-2-01Consejería de Educación, Junta de Castilla y León (Consejería de Educación de la Junta de Castilla y León) CSI018P23Fundación Científica Asociación Española Contra el Cáncer (Scientific Foundation, Spanish Association Against Cancer) EPAEC222641CICSFundación Científica Asociación Española Contra el Cáncer (Scientific Foundation, Spanish Association Against Cancer) GC16173472GARC"la Caixa" Foundation (Caixa Foundation) HR20-00164Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) PID2021-122666OB-I00Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) PLEC2022-009217
6 · The paper itself

Abstract

R-RAS2/TC21, a member of the R-RAS subfamily of GTP-binding proteins, shares structural and signaling properties with the RAS subfamily proteins H-, K-, and N-RAS. However, little information is available regarding its role in normal cells and the level of functional redundancy with R-RAS and classical RAS proteins. In this work, we used loss and gain-of-function approaches to assess these issues in mouse embryonic fibroblasts (MEFs). Using primary MEFs from Rras2

Indexed as

Cell Cycle CheckpointsFibroblastsMonomeric GTP-Binding Proteinsras ProteinsAnimalsCell AdhesionCell ProliferationEmbryo, MammalianMiceMice, KnockoutPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktras-GRF1Signal TransductionMonomeric GTP-Binding ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktras-GRF1Rasgrf1 protein, mouseras Proteins

Identifiers

PMID40164870
PMCPMC12143975

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.